These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 11038208

  • 1. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
    Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Kuma S, Kuma K, Futami H, Yamaguchi K.
    World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
    [Abstract] [Full Text] [Related]

  • 2. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations.
    Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K.
    World J Surg; 2002 Aug; 26(8):1023-8. PubMed ID: 12016484
    [Abstract] [Full Text] [Related]

  • 3. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF.
    Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
    Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG.
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
    [Abstract] [Full Text] [Related]

  • 12. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F.
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [Abstract] [Full Text] [Related]

  • 13. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M, Weinhüsel A, Niederle B, Haas OA.
    Int J Cancer; 1996 Aug 22; 69(4):312-6. PubMed ID: 8797874
    [Abstract] [Full Text] [Related]

  • 14. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
    Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA.
    Oncogene; 1997 Jun 26; 14(25):3103-6. PubMed ID: 9223675
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma.
    Huang CN, Wu SL, Chang TC, Huang SH, Chang TJ.
    J Formos Med Assoc; 1998 Aug 26; 97(8):541-6. PubMed ID: 9747064
    [Abstract] [Full Text] [Related]

  • 17. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
    Ruiz A, Antiñolo G, Fernández RM, Eng C, Marcos I, Borrego S.
    Clin Endocrinol (Oxf); 2001 Sep 26; 55(3):399-402. PubMed ID: 11589684
    [Abstract] [Full Text] [Related]

  • 18. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 19. Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers.
    Ukkat J, Lorenz K, Hinze R, Thomusch O, Dralle H.
    World J Surg; 2001 Jun 01; 25(6):713-7. PubMed ID: 11376404
    [Abstract] [Full Text] [Related]

  • 20. [Usefulness of RET proto-oncogene in the diagnosis of hereditary-type medullary carcinoma of the thyroid. Correlation with surgical findings].
    Carreño M, Girbés J, Malluguiza R, Serrano S, Matias-Guiu X, Tudela J, Alfayate R, Lagarda H.
    Acta Otorrinolaringol Esp; 2001 Jun 01; 52(1):57-63. PubMed ID: 11269881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.